Kerr Financial Planning’s Novartis NVS Stock Holding History

Kerr Financial Planning’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7	Closed	-$1.08K	–	529
2025 Q4	$1.08K	Sell	7 -19	-73%	-$2.49K	﹤0.01%	462
2025 Q3	$3.46K	Buy	+26	New	+$3.17K	﹤0.01%	442

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kerr Financial Planning's NVS Position: Q1 2026 in Review

Kerr Financial Planning sold out of Novartis (NVS) in Q1 2026, closing a stake of 7 shares — an estimated $1.08K sold.

Kerr Financial Planning first reported a position in NVS in Q3 2025 and held it in 2 quarters. The position peaked at $3.46K in Q3 2025. 1,599 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Kerr Financial Planning reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
Kerr Financial Planning sold 7 Novartis shares in Q1 2026, an estimated $1.08K.
Kerr Financial Planning first reported a position in Novartis in Q3 2025 and held it in 2 quarters.
Kerr Financial Planning's Novartis position peaked at $3.46K in Q3 2025.
1,599 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Kerr Financial Planning's 13F filing for Q1 2026, filed 29 Apr 2026.